TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
TRVI

Trevi Therapeutics Inc

Healthcare · Biotechnology

15.20$ +1.3% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Trevi Therapeutics Inc (TRVI)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 83.0% of the shares are freely tradable; institutional investors hold 98.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 98.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 83.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 9.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 143Mio.

Largest Shareholders

Institutions

Institutions TRVI
Name Stake (%) Shares Change (%) Date
NEA Management Company, LLC 9.28 13,222,228 +0.0 03/31/2026
BlackRock Inc 7.19 10,240,186 +1.1 03/31/2026
Frazier Life Sciences Management, L.P. 6.98 9,939,547 -3.1 03/31/2026
FMR Inc 5.64 8,038,061 +23.7 03/31/2026
Wellington Management Company LLP 3.99 5,684,592 +9.5 06/30/2026
Vivo Capital, LLC 3.58 5,094,668 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.49 4,978,567 +0.0 03/31/2026
Marshall Wace Asset Management Ltd 2.78 3,966,019 -13.4 03/31/2026
Rubric Capital Management LP 2.61 3,712,373 -1.4 03/31/2026

Funds

Funds TRVI
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.85 4,066,421 +0.4 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?